It is associated with stratigraphic and geothermal studies in Pakistan, often appearing in technical datasets related to lithology prediction and energy production. Digital & Social Contexts
Recent supplemental applications (e.g., BLA 125031/S-0202) have added critical safety information to the drug's labeling, including increased risks of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) when used alongside chemotherapy or radiation for breast and lung cancer. Scientific Literature Identifier 125031
The number appears most prominently as a regulatory and scientific identifier, particularly within the medical and physical sciences. Pharmaceutical Identifier (BLA 125031) It is associated with stratigraphic and geothermal studies
In the medical field, is the Biologics License Application (BLA) number assigned by the FDA to Neulasta (pegfilgrastim) . 125031